Keyphrases
Indonesia
100%
Jakarta
28%
Lymphatic Filariasis
19%
Albendazole
18%
Falciparum Malaria
17%
Brugia Malayi
16%
Plasmodium Vivax
15%
Primaquine
15%
Plasmodium Falciparum
15%
Malaria
12%
Mass Drug Administration
12%
Helminth Infection
12%
Type 2 Diabetes Mellitus (T2DM)
11%
Microfilaria
11%
Diethylcarbamazine
10%
Interleukin-10
10%
Helminths
9%
Indonesian
9%
Chronic Pulmonary Aspergillosis
9%
Soil-transmitted Helminth Infections
8%
Schoolchildren
8%
Filarial Parasites
8%
Soil-transmitted Helminths
8%
Brugia
8%
Brugia Timori
7%
Randomized Controlled Trial
7%
Randomized Placebo-controlled Trial
7%
Toxoplasma Gondii (T. gondii)
7%
Immune Response
7%
Diabetic Foot Ulcer
7%
Aspergillus
6%
Filarial
6%
Radical Cure
6%
Elephantiasis
6%
Filariasis
6%
HIV Patients
6%
IgG4-related Disease (IgG4-RD)
6%
COVID-19
6%
Interleukin-6
6%
Placebo
6%
Candida Albicans (C. albicans)
6%
Hyaluronic Acid
6%
Individual Patient Data Meta-analysis
6%
Deworming
6%
Southwest Sumba
6%
Propolis
6%
Cluster Randomized Trial
6%
Platelet-rich Fibrin
6%
Intestinal Parasitic Infections
6%
Interferon-α (IFN-α)
5%
Diarrhea
5%
Ascaris Lumbricoides
5%
Dengue Fever
5%
Pada
5%
AIDS/HIV
5%
Risk Factors
5%
Quantitative PCR
5%
Irian Jaya
5%
Peripheral Blood Mononuclear Cells
5%
Candida
5%
Permethrin
5%
Insulin Resistance
5%
IgG4 Antibodies
5%
Filaria
5%
Cryptosporidium
5%
Tuberculosis Patients
5%
Eastern Indonesia
5%
Stool Samples
5%
Pulmonary Tuberculosis
5%
Antifungal Activity
5%
Parasitemia
5%
Rural Areas
5%
Wuchereria Bancrofti
5%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
25%
Prevalence
19%
Primaquine
15%
Diseases
15%
Albendazole
14%
Helminthiasis
11%
Placebo
11%
Malaria Falciparum
11%
Drug Administration
10%
Helminth
10%
Plasmodium Vivax Malaria
10%
Lymphatic Filariasis
9%
Randomized Controlled Trial
9%
Antimalarial Agent
9%
Cross-Sectional Study
8%
Plasmodium vivax
8%
Aspergillus
7%
Candida Albicans
7%
Propolis
7%
Candida
7%
Diethylcarbamazine
6%
Combination Therapy
6%
Interleukin 6
6%
HIV
6%
Lung Aspergillosis
6%
Plasmodium falciparum
6%
Parasitemia
6%
Artemisinin
6%
Cyclorphan
5%
Enzyme-Linked Immunosorbent Assay
5%
Inflammation
5%
Platelet-Rich Fibrin
5%
Adverse Event
5%
Tumor Necrosis Factor
5%
Brugian Filariasis
5%
Anemia
5%
Non Insulin Dependent Diabetes Mellitus
5%
Microfilaria
5%
Antifungal Activity
5%
Recurrent Disease
5%
Medicine and Dentistry
Infection
15%
Prevalence
13%
Helminthiasis
11%
Helminth
11%
Albendazole
10%
Diseases
9%
Lymphatic Filariasis
9%
Cross Sectional Study
7%
Intestinal Parasite
7%
Diabetic Foot Ulcer
7%
Drug Administration
7%
Human Immunodeficiency Virus
7%
Randomized Controlled Trial
6%
Platelet-Rich Fibrin
6%
Diarrhea
6%
Parasitic Disease
6%
Malaria Falciparum
6%
Placebo
6%
Brugia malayi
5%
COVID-19
5%
Maturity Onset Diabetes of the Young
5%
Restylane
5%
Diethylcarbamazine
5%
Insulin Resistance
5%